First PhIII data with Lilly/Incyte's oral JAK inhibitor impresses in rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
Eli Lilly and Incyte's baricitinib has met the primary endpoint in the first Phase III data readout for the oral JAK inhibitor. The RA-BEACON study, in moderate to severe rheumatoid arthritis patients, showed baricitinib significantly improved ACR20 response compared to placebo after 12 weeks of treatment.